NOVARTIS Company Profile
✉ Email this page to a colleague
What is the competitive landscape for NOVARTIS, and when can generic versions of NOVARTIS drugs launch?
NOVARTIS has one hundred and eighty-five approved drugs.
There are one hundred and three US patents protecting NOVARTIS drugs.
There are two thousand seven hundred and forty-eight patent family members on NOVARTIS drugs in sixty-nine countries and five hundred and twenty supplementary protection certificates in nineteen countries.
Summary for NOVARTIS
International Patents: | 2748 |
US Patents: | 103 |
Tradenames: | 154 |
Ingredients: | 139 |
NDAs: | 185 |
Drug Master File Entries: | 1 |
Patent Litigation for NOVARTIS: | See patent lawsuits for NOVARTIS |
PTAB Cases with NOVARTIS as patent owner: | See PTAB cases with NOVARTIS as patent owner |
Drugs and US Patents for NOVARTIS
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novartis | TAFINLAR | dabrafenib mesylate | CAPSULE;ORAL | 202806-001 | May 29, 2013 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Novartis | LIORESAL | baclofen | TABLET;ORAL | 017851-003 | Jan 20, 1982 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Novartis | PROMACTA | eltrombopag olamine | TABLET;ORAL | 022291-001 | Nov 20, 2008 | RX | Yes | No | 7,547,719*PED | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Novartis | MESANTOIN | mephenytoin | TABLET;ORAL | 006008-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Novartis | MEKINIST | trametinib dimethyl sulfoxide | TABLET;ORAL | 204114-002 | May 29, 2013 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Novartis | FLUOR-OP | fluorometholone | SUSPENSION/DROPS;OPHTHALMIC | 070185-001 | Feb 27, 1986 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for NOVARTIS
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Novartis | GILENYA | fingolimod hydrochloride | CAPSULE;ORAL | 022527-002 | May 11, 2018 | 5,604,229*PED | ⤷ Try a Trial |
Novartis | AFINITOR | everolimus | TABLET;ORAL | 022334-001 | Mar 30, 2009 | 6,004,973*PED | ⤷ Try a Trial |
Novartis | PROMACTA KIT | eltrombopag olamine | FOR SUSPENSION;ORAL | 207027-001 | Aug 24, 2015 | 7,795,293*PED | ⤷ Try a Trial |
Novartis | GLEEVEC | imatinib mesylate | TABLET;ORAL | 021588-002 | Apr 18, 2003 | 7,544,799*PED | ⤷ Try a Trial |
Novartis | EXELON | rivastigmine tartrate | CAPSULE;ORAL | 020823-003 | Apr 21, 2000 | 4,948,807 | ⤷ Try a Trial |
Novartis | SANDOSTATIN | octreotide acetate | INJECTABLE;INJECTION | 019667-005 | Jun 12, 1991 | 4,395,403 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for NOVARTIS drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets for Oral Suspension | 2 mg, 3 mg and 5 mg | ➤ Subscribe | 2016-12-30 |
➤ Subscribe | Transdermal System Extended-release | 13.3 mg/24 hr | ➤ Subscribe | 2013-01-22 |
➤ Subscribe | Tablets | 2.5 mg, 5 mg, and 7.5 mg | ➤ Subscribe | 2014-12-10 |
➤ Subscribe | Tablets | 90 mg and 360 mg | ➤ Subscribe | 2015-10-19 |
➤ Subscribe | Tablets | 100 mg and 400 mg | ➤ Subscribe | 2007-03-12 |
➤ Subscribe | Tablets | 320 mg/12.5 mg and 320 mg/25 mg | ➤ Subscribe | 2007-02-07 |
➤ Subscribe | Tablets | 180 mg | ➤ Subscribe | 2016-04-28 |
➤ Subscribe | Capsules | 20 mg and 40 mg | ➤ Subscribe | 2008-06-04 |
➤ Subscribe | Tablets | 5 mg/320 mg | ➤ Subscribe | 2007-11-26 |
➤ Subscribe | Injection | 0.8 mg (base) /mL | ➤ Subscribe | 2008-06-11 |
➤ Subscribe | Tablets | 10 mg/320 mg | ➤ Subscribe | 2007-11-09 |
➤ Subscribe | Ophthalmic Solution | 0.003% | ➤ Subscribe | 2015-12-30 |
➤ Subscribe | Tablets | 10 mg/12.5 mg/160 mg | ➤ Subscribe | 2009-10-22 |
➤ Subscribe | Tablets | 150 mg, 300 mg and 600 mg | ➤ Subscribe | 2006-05-05 |
➤ Subscribe | Tablets | 50 mg and 75 mg | ➤ Subscribe | 2014-01-07 |
➤ Subscribe | Delayed-release Tablets | 360 mg | ➤ Subscribe | 2009-02-02 |
➤ Subscribe | Tablets | 60 mg and 120 mg | ➤ Subscribe | 2004-12-22 |
➤ Subscribe | Tablets | 40 mg, 80 mg,160 mg | ➤ Subscribe | 2004-12-28 |
➤ Subscribe | Extended-release Tablets | 100 mg | ➤ Subscribe | 2005-12-30 |
➤ Subscribe | Tablets | 0.25 mg, 0.5 mg, and 0.75 mg | ➤ Subscribe | 2013-09-30 |
➤ Subscribe | Oral Solution | 2 mg/mL | ➤ Subscribe | 2004-11-05 |
➤ Subscribe | Tablets | 10 mg | ➤ Subscribe | 2014-06-18 |
➤ Subscribe | Tablets | 2.5 mg | ➤ Subscribe | 2006-03-02 |
➤ Subscribe | Capsules | 0.5 mg | ➤ Subscribe | 2014-09-22 |
➤ Subscribe | Tablets | 80 mg/12.5 mg, 160 mg/12.5 mg and 160 mg/25 mg | ➤ Subscribe | 2005-12-02 |
➤ Subscribe | Tablets | 180 mg | ➤ Subscribe | 2015-10-23 |
➤ Subscribe | Capsules | 400 mg | ➤ Subscribe | 2014-01-24 |
➤ Subscribe | Tablets | 5 mg/160 mg | ➤ Subscribe | 2007-10-22 |
➤ Subscribe | Capsules | 150 mg and 200 mg | ➤ Subscribe | 2013-01-29 |
➤ Subscribe | Tablets | 10 mg/160 mg | ➤ Subscribe | 2007-10-01 |
➤ Subscribe | Injection | 4 mg/100 mg, 100 mL vial | ➤ Subscribe | 2012-01-31 |
➤ Subscribe | Tablets | 5 mg/12.5 mg/160 mg, 5 mg/25 mg/160 mg, 10 mg/25 mg/160 mg and 10 mg/25 mg/320 m | ➤ Subscribe | 2009-09-14 |
➤ Subscribe | Nasal Spray | 0.665 mg/ Spray | ➤ Subscribe | 2009-06-29 |
➤ Subscribe | Tablets | 125 mg, 250 mg and 500 mg | ➤ Subscribe | 2004-12-28 |
➤ Subscribe | Oral Suspension | 300 mg/5 mL | ➤ Subscribe | 2006-12-26 |
➤ Subscribe | Tablets | 12.5 mg and 25 mg | ➤ Subscribe | 2014-02-04 |
➤ Subscribe | Delayed-release Tablets | 180 mg | ➤ Subscribe | 2009-06-04 |
➤ Subscribe | Tablets | 250 mg | ➤ Subscribe | 2011-03-14 |
➤ Subscribe | Capsules | 1.5 mg, 3 mg, 4.5 mg and 6 mg | ➤ Subscribe | 2004-04-21 |
➤ Subscribe | Tablets | 125 mg, 250 mg, and 500 mg | ➤ Subscribe | 2011-10-28 |
International Patents for NOVARTIS Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Mexico | 2011002988 | ⤷ Try a Trial |
Lithuania | 2929031 | ⤷ Try a Trial |
Brazil | PI0722383 | ⤷ Try a Trial |
Taiwan | I353857 | ⤷ Try a Trial |
Argentina | 043987 | ⤷ Try a Trial |
Lithuania | 3121171 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for NOVARTIS Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0398460 | 04C0022 | France | ⤷ Try a Trial | PRODUCT NAME: ESTRADIOL ANHYDRE DROSPIRENONE; REGISTRATION NO/DATE IN FRANCE: NL 28661 DU 20040316; REGISTRATION NO/DATE AT EEC: RVG 27505 DU 20021211 |
1915993 | CA 2013 00062 | Denmark | ⤷ Try a Trial | PRODUCT NAME: KOMBINATION OMFATTENDE ALISKIREN, ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER HEMIFUMARAT, OG AMLODIPIN, ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER BENSYLAT; REG. NO/DATE: EU/1/11/686/001/056 20110418 |
2331537 | CA 2020 00054 | Denmark | ⤷ Try a Trial | PRODUCT NAME: ALPELISIB ELLER ET FARMACEUTISK ACCEPTABELT SALT HERAF; REG. NO/DATE: EU/1/20/1455 20200728 |
2099447 | CR 2022 00053 | Denmark | ⤷ Try a Trial | PRODUCT NAME: CAPMATINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/22/1650 20220621 |
2099447 | PA2022527 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: KAPMATINIBAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/22/1650 20220620 |
2379069 | 2020017 | Norway | ⤷ Try a Trial | PRODUCT NAME: SIPONIMOD; REG. NO/DATE: EU/1/19/1414 20200127 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.